Source: International Congress 2016 – Therapeutic trials in lung cancer
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Jean-Paul Sculier (Brussels, Belgium), Jean-Paul Sculier, Jean-Jacques Lafitte, Anne-Pascale Meert, Vicente Giner, Jacques Lecomte, Arnaud Scherpereel, Marianne Paesmans, Nathalie Leclercq, Thierry Berghmans. A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC). Eur Respir J 2016; 48: Suppl. 60, 3345

Member's Comments

No comment yet.

Related content which might interest you: Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 The role of second line chemotherapy in small cell lung cancer: A retrospective analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Treatment of advanced non-small cell lung cancer with trofosfamide Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Surgical treatment outcomes on early-stages of non-small-cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 A prospective study of survival after surgery for early stage non-small cell lung cancer in patients with COPD Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery Year: 2015 Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy? Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Outcomes of radical treatment of early stage non-small cell lung cancer Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Lung cancer risk prediction model based on data of the SOS trial (single center non-randomized lung cancer early detection trial) Source: International Congress 2014 – Risk assessment and tracheal reconstructions Year: 2014 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Pulmonary function during lung cancer therapy: A retrospective analysis of patients treated with monotherapy or multimodal treatments Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013